Levi & Korsinsky Investigating Whether PROCEPT BioRobotics Corporation (PRCT) Misled Investors - Securities Law Violations Possible

On the Q3 2025 earnings call on November 4, 2025, CFO Kevin Waters (Waters Aktie) reaffirmed the $325.5 million revenue target (Target Aktie) and stated the company was "maintaining handpiece average selling prices to be approximately $3,200." CEO Larry Wood added that investments in strategic priorities were "not expect[ed] ... to impede our progress toward achieving profitability." At the time of these statements, the Company had implemented a pricing-discipline initiative that eliminated historical bulk-purchase discounts -- a change that directly reduced realized average selling prices on the Company's core product line.

The guidance did not quantify or disclose the revenue impact of this pricing change. When Q4 2025 results were released, actual revenue fell $17.4 million short of the guided figure, and FY 2026 guidance of $410 million to $430 million also came in below analyst consensus. The stock lost roughly 15% of its value in a single session.

If you suffered a loss on your PROCEPT BioRobotics Corporation securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288647